Exenatide, a 39-amino acid peptide used for treatment of type 2 diabetes, is known to inhibit gastric emptying and as a result to alter the absorption of orally administered concomitant medications. After subcutaneous administration, exenatide is rapidly absorbed, usually reaching peak concentrations 2 hours postadministration. It is eliminated renally with a 2.5 hr half-life. The aim of our study was to build a model of delayed gastric emptying caused by exenatide that could be applied to any drug co-administered with it, and would allow predicting its effect on the drug’s pharmacokinetics.
American Association of Pharmaceutical Scientists (AAPS), November 17-19, 2008, Atlanta, GA
By Grazyna Fraczkiewicz, Neil Parrott, Thierry Lave, Viera Lukacova, Michael B. Bolger, John R. Crison, & Walter S. Woltosz